-eluting stents vs.
bypass surgery in patients with the most complex coronary artery disease --
left main stenosis and three-vessel disease. Today's presentation revealed
findings for the primary endpoint, focusing on the safety and effectiveness
of the two therapies and whether either group experienced more heart
attack, stroke, or death, or was more likely to require repeat
revascularization procedures (either a second PCI or bypass surgery) by the
end of the first year.
In its head-to-head comparison of PCI vs. bypass surgery, SYNTAX found
no statistically significant difference in risk of death (4.3% vs. 3.5%,
respectively; p=0.37) or heart attack (4.8% vs. 3.2%, respectively,
p=0.11). The risk of stroke was significantly greater for bypass surgery
(0.6% for PCI vs. 2.2% for bypass; p=0.003). Taken together as a composite,
these three data points (death, heart attack, and stroke) show that PCI and
bypass surgery stack up overall as equally safe options for patients with
left main and multi-vessel coronary artery disease.
Less than 8% more PCI than bypass patients underwent either a second
angioplasty procedure or bypass surgery by the end of the year following
their procedure. "Historically speaking, this is remarkable," says Dr.
Feldman. "It means that more than 85% of patients can choose the
less-invasive angioplasty / stenting option and won't need another
procedure a year later. On the revascularization question, we've never seen
such a small difference between PCI and bypass surgery, even in less
complex patients."
SCAI urges all patients and their physicians to consider the broad
spectrum of care for treatment of cardiovascular disease, stressing that no
single therapy is best for every patient. "All patients need to talk with
their doctors about the best options for them as individuals, considering
the status of their health and their desired outcomes for quality of life,"
says Dr. Ziyad M. Hijazi, SCAI President, Director of the Rush
'/>"/>
SOURCE Society for Cardiovascular Angiography and Interventions(SCAI) Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI2.
New AVAC Report on Pre-Exposure Prophylaxis Calls for Immediate Planning to Anticipate Study Results of Potential New HIV Prevention Option3.
ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer4.
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma5.
Roche Exercises its Option to Further Develop and Commercialize Memory Pharmaceuticals Nicotinic Alpha-7 Agonist, MEM 34546.
Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics7.
Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes8.
GSK Does Not Option XL784 for Further Development9.
American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation10.
Prasugrel Head-to-Head Study Showed Reduced Cardiovascular Events in Diabetes Patients by 30 Percent Compared with Clopidogrel11.
CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System